Description

GLP-1R is a novel triple agonist peptide designed to activate the GLP-1, GIP, and glucagon receptors. This triagonist mechanism has shown promise in preclinical and clinical research for regulating appetite, enhancing energy expenditure, and promoting significant reductions in body weight and fat mass.

By simultaneously targeting multiple metabolic pathways, Retatrutide is being investigated for its potential in research models related to obesity, insulin resistance, and cardiometabolic health.

Mechanism of Action (Based on Preclinical and Early Clinical Research):

• GLP-1 Receptor Agonism: Slows gastric emptying and increases satiety

• GIP Receptor Agonism: Enhances insulin secretion and energy balance

• Glucagon Receptor Agonism: Increases energy expenditure and fat oxidation

Potential Benefits (Based on Research Studies):

• Significant weight loss through appetite suppression and increased fat metabolism

• Improved insulin sensitivity and glucose regulation

• Reduction in visceral and subcutaneous fat stores

• Enhanced cardiometabolic biomarkers in obesity models

⚠️ For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended strictly for laboratory research purposes.